Md Mahadi Hasan

h-index10
2papers

2 Papers

58.3CEMar 19
FinTradeBench: A Financial Reasoning Benchmark for LLMs

Yogesh Agrawal, Aniruddha Dutta, Md Mahadi Hasan et al.

Real-world financial decision-making is a challenging problem that requires reasoning over heterogeneous signals, including company fundamentals derived from regulatory filings and trading signals computed from price dynamics. Recently, with the advancement of Large Language Models (LLMs), financial analysts have begun to use them for financial decision-making tasks. However, existing financial question answering benchmarks for testing these models primarily focus on company balance sheet data and rarely evaluate reasoning over how company stocks trade in the market or their interactions with fundamentals. To take advantage of the strengths of both approaches, we introduce FinTradeBench, a benchmark for evaluating financial reasoning that integrates company fundamentals and trading signals. FinTradeBench contains 1,400 questions grounded in NASDAQ-100 companies over a ten-year historical window. The benchmark is organized into three reasoning categories: fundamentals-focused, trading-signal-focused, and hybrid questions requiring cross-signal reasoning. To ensure reliability at scale, we adopt a calibration-then-scaling framework that combines expert seed questions, multi-model response generation, intra-model self-filtering, numerical auditing, and human-LLM judge alignment. We evaluate 14 LLMs under zero-shot prompting and retrieval-augmented settings and witness a clear performance gap. Retrieval substantially improves reasoning over textual fundamentals, but provides limited benefit for trading-signal reasoning. These findings highlight fundamental challenges in the numerical and time-series reasoning for current LLMs and motivate future research in financial intelligence.

APJun 23, 2025
A Machine Learning Framework for Breast Cancer Treatment Classification Using a Novel Dataset

Md Nahid Hasan, Md Monzur Murshed, Md Mahadi Hasan et al.

Breast cancer (BC) remains a significant global health challenge, with personalized treatment selection complicated by the disease's molecular and clinical heterogeneity. BC treatment decisions rely on various patient-specific clinical factors, and machine learning (ML) offers a powerful approach to predicting treatment outcomes. This study utilizes The Cancer Genome Atlas (TCGA) breast cancer clinical dataset to develop ML models for predicting the likelihood of undergoing chemotherapy or hormonal therapy. The models are trained using five-fold cross-validation and evaluated through performance metrics, including accuracy, precision, recall, specificity, sensitivity, F1-score, and area under the receiver operating characteristic curve (AUROC). Model uncertainty is assessed using bootstrap techniques, while SHAP values enhance interpretability by identifying key predictors. Among the tested models, the Gradient Boosting Machine (GBM) achieves the highest stable performance (accuracy = 0.7718, AUROC = 0.8252), followed by Extreme Gradient Boosting (XGBoost) (accuracy = 0.7557, AUROC = 0.8044) and Adaptive Boosting (AdaBoost) (accuracy = 0.7552, AUROC = 0.8016). These findings underscore the potential of ML in supporting personalized breast cancer treatment decisions through data-driven insights.